233 related articles for article (PubMed ID: 18446392)
1. An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event.
Tavakoli M; Pumford N; Woodward M; Doney A; Chalmers J; MacMahon S; Macwalter R
Eur J Health Econ; 2009 Feb; 10(1):111-9. PubMed ID: 18446392
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
McInnes G; Burke TA; Carides G
J Hum Hypertens; 2006 Jan; 20(1):51-8. PubMed ID: 16357874
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
[TBL] [Abstract][Full Text] [Related]
4. PROGRESS - Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Progress Management Committee.
J Hypertens; 1999 Nov; 17(11):1647-55. PubMed ID: 10608480
[TBL] [Abstract][Full Text] [Related]
5. PROGRESS--perindopril protection against recurrent stroke study: status in July 1996. PROGRESS Management Committee.
J Hypertens Suppl; 1996 Dec; 14(6):S47-51. PubMed ID: 9023716
[TBL] [Abstract][Full Text] [Related]
6. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
Whitfield MD; Gillett M; Holmes M; Ogden E
Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.
Briggs A; Mihaylova B; Sculpher M; Hall A; Wolstenholme J; Simoons M; Deckers J; Ferrari R; Remme WJ; Bertrand M; Fox K;
Heart; 2007 Sep; 93(9):1081-6. PubMed ID: 17135223
[TBL] [Abstract][Full Text] [Related]
8. PROGRESS (Perindopril Protection Against Recurrent Stroke Study): regional characteristics of the study population at baseline. PROGRESS Management Committee.
Chalmers J; Neal B; MacMahon S;
J Hypertens Suppl; 2000 May; 18(1):S13-9. PubMed ID: 10939785
[TBL] [Abstract][Full Text] [Related]
9. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy.
Dufouil C; Chalmers J; Coskun O; Besançon V; Bousser MG; Guillon P; MacMahon S; Mazoyer B; Neal B; Woodward M; Tzourio-Mazoyer N; Tzourio C;
Circulation; 2005 Sep; 112(11):1644-50. PubMed ID: 16145004
[TBL] [Abstract][Full Text] [Related]
10. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.
PROGRESS Collaborative Group
Lancet; 2001 Sep; 358(9287):1033-41. PubMed ID: 11589932
[TBL] [Abstract][Full Text] [Related]
11. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).
Houle SK; Chuck AW; McAlister FA; Tsuyuki RT
Pharmacotherapy; 2012 Jun; 32(6):527-37. PubMed ID: 22552863
[TBL] [Abstract][Full Text] [Related]
12. Global impact of stroke.
Chalmers J
Heart Dis; 2000; 2(2):S13-7. PubMed ID: 11728258
[TBL] [Abstract][Full Text] [Related]
13. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.
Brugts JJ; Ninomiya T; Boersma E; Remme WJ; Bertrand M; Ferrari R; Fox K; MacMahon S; Chalmers J; Simoons ML
Eur Heart J; 2009 Jun; 30(11):1385-94. PubMed ID: 19346520
[TBL] [Abstract][Full Text] [Related]
14. Stroke secondary prevention and blood pressure reduction: an observational study of the use of PROGRESS therapy.
Bugnicourt JM; Chillon JM; Canaple S; Lamy C; Godefroy O
Fundam Clin Pharmacol; 2008 Apr; 22(2):217-22. PubMed ID: 18353116
[TBL] [Abstract][Full Text] [Related]
15. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy.
Dolan E; Stanton AV; Thom S; Caulfield M; Atkins N; McInnes G; Collier D; Dicker P; O'Brien E;
J Hypertens; 2009 Apr; 27(4):876-85. PubMed ID: 19516185
[TBL] [Abstract][Full Text] [Related]
16. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study.
Perkovic V; Ninomiya T; Arima H; Gallagher M; Jardine M; Cass A; Neal B; Macmahon S; Chalmers J
J Am Soc Nephrol; 2007 Oct; 18(10):2766-72. PubMed ID: 17804673
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
18. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial.
Chapman N; Huxley R; Anderson C; Bousser MG; Chalmers J; Colman S; Davis S; Donnan G; MacMahon S; Neal B; Warlow C; Woodward M;
Stroke; 2004 Jan; 35(1):116-21. PubMed ID: 14671247
[TBL] [Abstract][Full Text] [Related]
19. Effects of a perindopril-based blood pressure-lowering regimen on disability and dependency in 6105 patients with cerebrovascular disease: a randomized controlled trial.
Fransen M; Anderson C; Chalmers J; Chapman N; Davis S; MacMahon S; Neal B; Sega R; Terent A; Tzourio C; Woodward M;
Stroke; 2003 Oct; 34(10):2333-8. PubMed ID: 12958329
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
